AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
Price Chart
Executive Summary
Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation BCR-ABL1 inhibitor) and lisaftoclax (Bcl-2 inhibitor) across multiple hematologic malignancies. Olverembatinib showed statistically superior MMR rates vs standard TKI continuation in a controlled CML-CP trial (54.3% vs 10.0% at 6 months, P<0.001), and the POLARIS-1 Ph+ ALL study achieved 94.4% CR/CRi; lisaftoclax real-world AML data showed a 72% CR/CRi rate. Both assets remain investigational in the US with no FDA action date announced.
Actionable Insight
No financial data or catalysts were provided — this is a clinical data update only. Monitor for full POLARIS-1/2/3 data at future medical meetings and any FDA regulatory milestones (no PDUFA date set). The stock has historically fallen ~10% in the 5 days following prior reports on this ticker; traders should note the lack of hard catalyst here may lead to a similar neutral-to-negative drift.
Key Facts
- Olverembatinib demonstrated a 54.3% 6-month MMR rate vs 10.0% in a controlled CML-CP trial (P<0.001)
- POLARIS-1 Ph+ ALL front-line study: 94.4% CR/CRi, 63.0% MRD-negative CR at end of induction
- Lisaftoclax real-world AML cohort: 72% CR/CRi, 61% MRD-negativity in responders
- Lisaftoclax Phase II CLL/SLL: median PFS 23.9 months, ORR 62.5% in BTKi-refractory patients
- Olverembatinib + lisaftoclax chemo-free combo in pediatric R/R Ph+ ALL yielded 88.9% ORR
- Both assets remain unapproved by US FDA — no approval or CRL event
Financial Impact
No financial results, guidance, or deal values were disclosed in this press release.
Risk Factors
- Both assets are not US FDA-approved — regulatory risk remains for POLARIS-1/2/3 trials
- No financial data or guidance was provided; stock may drift on lack of monetization catalyst
- Historical T+5 performance on prior AAPG reports has been negative (avg -10%)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311475 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 15, 2026
3d ago
|
6-K
| $17.34 $17.01 | ▼ −1.90% | ▼ −1.31% | $17.09 (−1.44%) |
|
Jun 14, 2026
4d ago
|
Press Release
| $17.34 $17.01 | ▼ −1.90% | ▼ −1.31% | $17.09 (−1.44%) |
|
Jun 1, 2026
17d ago
|
6-K
| $19.08 $18.45 | ▼ −3.30% | ▼ −3.45% | $17.09 (−10.43%) |
|
May 28, 2026
21d ago
|
6-K
| $20.01 $19.08 | ▼ −4.65% | ▼ −4.91% | $17.09 (−14.59%) |
|
May 28, 2026
21d ago
|
6-K
| $19.88 $20.01 | ▲ +0.65% | ▲ +0.41% | $17.09 (−14.03%) |
|
May 22, 2026
27d ago
|
6-K
| $21.01 $20.13 | ▼ −4.20% | ▼ −4.79% | $17.09 (−18.66%) |
|
May 22, 2026
28d ago
|
Press Release
| $21.01 $20.13 | ▼ −4.20% | ▼ −4.79% | $17.09 (−18.66%) |
|
May 13, 2026
5w ago
|
6-K
| $21.38 $20.18 | ▼ −5.61% | ▼ −6.39% | $17.09 (−20.07%) |
|
May 12, 2026
5w ago
|
6-K
| $21.16 $21.38 | ▲ +1.04% | ▲ +0.46% | $17.09 (−19.23%) |
|
Apr 22, 2026
8w ago
|
6-K
| $25.13 $22.34 | ▼ −11.10% | ▼ −10.71% | $17.09 (−31.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access